In low-risk patients, there was a very low incidence of greater than moderate leak, including in patients with minimal oversizing. The degree of prosthesis oversizing had a great impact on mild paravalvular leak reduction and the need for post-dilation without changing valve hemodynamics. This research investigated the impact of the perimeter and the area, measured<a href="https://solaci.org/en/2021/12/03/prosthesis-annular-size-ratio-and-its-impact-on-leaks/" title="Read more" >...</a>
True left main stem bifurcation patients have shown fewer adverse events with stepwise provisional stenting vs systematic dual stenting as first strategy, even though the difference was not significant. Usually, for any other vessel, the preferred technique is provisional stenting. However, when it comes to the left main, there is a randomized, dedicated, well designed<a href="https://solaci.org/en/2021/11/30/provisional-vs-dual-stenting-in-left-main-an-endless-discussion/" title="Read more" >...</a>
Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition. While their significance in COVID cases is backed by the literature, there was not<a href="https://solaci.org/en/2021/11/03/is-troponin-elevation-after-tavr-related-to-mortality/" title="Read more" >...</a>
Ideally, we will not puncture the femoral artery blindly if we are planning to use a big caliber releasing device and a percutaneous closure device during TAVR. The risk of a high or low puncture or the presence of a lateral branch compromising the puncture site might become a major vascular and bleeding complication. There<a href="https://solaci.org/en/2021/10/28/fluoroscopy-vs-ultrasound-guided-femoral-access-in-tavr/" title="Read more" >...</a>
The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three options available in clinical practice for transcatheter aortic valve replacement (TAVR) in the United States. For the time being, its indication will have some restrictions: for example, it can only be used in high-risk patients (unlike CoreValve and<a href="https://solaci.org/en/2021/10/06/the-fda-approves-a-third-device-in-the-tavr-race/" title="Read more" >...</a>
01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-<a href="https://solaci.org/en/2021/10/05/the-latest-scientific-articles-on-tavi-published-on-our-website/" title="Read more" >...</a>
01- ESC 2021 | Updated European Society of Cardiology Guidelines for the Management of Valvular Heart Disease Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European<a href="https://solaci.org/en/2021/10/01/the-most-read-scientific-papers-of-september-in-interventional-cardiology/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) is an increasingly frequent option for patients with severe aortic stenosis across the entire risk spectrum. However, TAVR involves bleeding and thrombosis risk and therefore calls for an optimal adjuvant treatment. Any scheme is complex if we take into account most patients undergoing TAVR are generally elderly and have multiple<a href="https://solaci.org/en/2021/09/21/thrombotic-and-bleeding-risk-after-tavr-quick-tips-to-stay-up-to-date/" title="Read more" >...</a>
Paravalvular regurgitation after transcatheter aortic valve replacement (TAVR) have historically been associated with worse clinical outcomes. Even mild leaks have been shown to be harmful. This study looked at a real-world experience with the transcatheter heart valve SAPIEN 3 Ultra in the US. The SAPIEN 3 Ultra is a new generation balloon-expandable heart valve with<a href="https://solaci.org/en/2021/09/17/sapien-3-ultra-lower-incidence-of-paravalvular-regurgitation/" title="Read more" >...</a>
✔️ Watch again the Catheterization and Cardiovascular Interventions (CCI) Session in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: 01:44 – The Hybrid Algorithm in Complex Chronic Total Occlusion Percutaneous Coronary Intervention: Experience of a Latin-American Centre – Héctor Hugo Escutia Cuevas 21:12 – SYNTAX score II application compared to GRACE score for prediction of Heart Failure<a href="https://solaci.org/en/2021/09/14/solaci-caci-2021-cci-session-2/" title="Read more" >...</a>